Morphine manifesto seeks to boost access to oral morphine

A group of global, regional, and national palliative care organisations has urged governments and regulators to take steps to end the practice of pharmaceutical companies marketing sustained-release morphine and expensive opioid formulations, and to ensure the availability of generic immediate-relea...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2024-01, Vol.25 (1), p.e5-e5
Main Author: Sharma, Dinesh C
Format: Article
Language:English
Subjects:
Controlled release
Marketing
Morphine
Narcotics
Oncology
Opioids
Palliative care
Pharmaceutical industry
Psychotropic drugs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A group of global, regional, and national palliative care organisations has urged governments and regulators to take steps to end the practice of pharmaceutical companies marketing sustained-release morphine and expensive opioid formulations, and to ensure the availability of generic immediate-release oral morphine for pain management. “Western pharmaceutical companies use aggressive marketing techniques to convince ministries of health in LMICs to license and import expensive opioid products, doctors to prescribe them, and patients to ask for them, even though they are no better and sometimes worse than morphine. “The idea is that any country able to demonstrate a secure supply chain (to minimise the risk of diversion of morphine to non-medical uses) should be eligible to participate in pooled purchasing.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(23)00645-9